Thai FDA requires every marketing authorization holder to maintain a functioning pharmacovigilance system from the date of approval. For new drugs, a mandatory Safety Monitoring Program (SMP) applies for a minimum of 2 years post-approval, during which the product can only be dispensed in hospitals. Adverse event reporting is not optional, and the timelines are strict.
Thai FDA's pharmacovigilance framework is built on the principle that registration approval is the beginning of the safety evaluation process, not the end. The data package submitted at registration reflects what was known about the product's safety profile at the time of approval. Post-marketing surveillance generates real-world safety data from the Thai patient population, which may differ in important ways from the populations studied in clinical trials.
The Marketing Authorization Holder (LAR) is the entity responsible for pharmacovigilance in Thailand. All adverse event reports, periodic safety updates, and safety-related communications with Thai FDA are the LAR's obligation. Foreign manufacturers who delegate pharmacovigilance to their LAR must ensure that the LAR has the systems and competence to fulfill these obligations in full: the legal exposure for non-compliance sits with the LAR, but the reputational and commercial consequences extend to the manufacturer.
Thai FDA has issued specific guidance for marketing authorization holders on post-marketing safety reporting. The framework draws on international pharmacovigilance principles, including ICH E2 guidelines, but applies them through Thai FDA's own reporting system and timelines.
All new drugs approved for marketing in Thailand are subject to a mandatory Safety Monitoring Program (SMP) for a minimum period of 2 years from the date of approval. The SMP is a condition of the marketing authorization, not a voluntary commitment. A product approved under an SMP condition is subject to specific restrictions and reporting obligations for the duration of the program.
During the SMP period, the drug may only be dispensed in hospitals. It cannot be distributed through retail pharmacies or sold directly to patients outside a hospital setting. This restriction is enforced as a condition of the marketing authorization. Distribution outside the approved channel during the SMP period constitutes a violation of the MA conditions and exposes the LAR to regulatory action.
The LAR must provide periodic safety updates to Thai FDA throughout the SMP period. These updates include adverse drug reaction data collected from the Thai market, a summary of any changes to the global safety profile of the product, and information on distribution volumes and reach. The reporting frequency and format are specified in the SMP conditions attached to the marketing authorization.
At the conclusion of the SMP period, the LAR must submit a comprehensive end-of-SMP package to Thai FDA. This package includes a Periodic Safety Update Report (PSUR) covering the full SMP period, a comprehensive summary of the product's safety profile based on Thai and global post-market data, and a summary of sales and distribution data for the SMP period. Thai FDA reviews this package before deciding whether to lift the SMP condition, extend the monitoring period, or impose additional post-market requirements.
If Thai FDA is satisfied with the end-of-SMP submission and the product's safety profile, the SMP condition is lifted and the product transitions to standard post-marketing surveillance. The LAR then manages ongoing pharmacovigilance under the standard framework, without the hospital dispensing restriction. If Thai FDA has concerns, the SMP period may be extended or additional conditions may be imposed before full registration status is granted.
Thai FDA requires that serious unexpected adverse drug reactions (suspected unexpected serious adverse reactions, or SUSARs) be reported within defined calendar day windows from the date the LAR first becomes aware of the event. These timelines are not targets: they are mandatory deadlines, and the clock starts from the moment the LAR has knowledge of the event, not from when it is confirmed or investigated.
For serious unexpected adverse reactions with a fatal or life-threatening outcome, a draft initial notification must be submitted to Thai FDA within 7 calendar days of the LAR first becoming aware of the event. The full, complete report must follow within an additional 8 calendar days, making a total of 15 calendar days for the complete report. This 7-day initial notification requirement is one of the strictest timelines in Thai FDA's pharmacovigilance framework.
For serious unexpected adverse reactions that are not fatal or immediately life-threatening, the complete report must be submitted to Thai FDA within 15 calendar days of the LAR first becoming aware of the event. A two-stage draft/final process is not required for this category, but the report must be complete and accurate within the 15-day window.
Adverse reactions that are already listed in the approved product information (expected reactions) or that are non-serious are not subject to expedited reporting timelines. They are captured and reported through the periodic safety reporting process. However, a pattern of expected reactions that appears to be occurring at a higher frequency than anticipated in the approved product information may trigger a requirement for expedited reporting or a variation to the label.
The LAR's pharmacovigilance system must capture adverse event reports from all sources: healthcare professionals, patients, distributors, and the foreign manufacturer's own global pharmacovigilance database. Reports received by the foreign manufacturer that concern a product marketed in Thailand must be forwarded to the Thai LAR for assessment and reporting to Thai FDA within the applicable timeline. A global pharmacovigilance system that does not include a mechanism for routing Thailand-relevant reports to the LAR is a structural gap in the pharmacovigilance process.
Thai FDA's standard position is that marketing authorization holders are not required to submit Periodic Benefit-Risk Evaluation Reports (PBRERs) or Periodic Safety Update Reports (PSURs) routinely unless Thai FDA specifically requests them, with the exception of the mandatory end-of-SMP PSUR described above. Risk Management Plans (RMPs) are similarly not required unless Thai FDA requests one.
Thai FDA may request a PSUR or PBRER for any product at any time, particularly if post-market data raises questions about the benefit-risk profile, if new safety information has emerged globally, or if the product has been subject to regulatory action in another market. When Thai FDA issues such a request, the LAR must be prepared to compile and submit the report within the timeframe specified. Maintaining an up-to-date global safety database that can generate a PSUR or PBRER efficiently is a practical necessity even if routine submission is not required.
A Risk Management Plan may be requested by Thai FDA for products with complex safety profiles, products approved under conditional or SMP status, or products where emerging post-market data suggests a specific risk requiring proactive management. The scope and format of a Thai FDA-requested RMP follows international guidelines but must address the specific Thai market context and the LAR's implementation capacity in Thailand.
The one mandatory PSUR in Thai FDA's framework, for all products, is the end-of-SMP submission. This PSUR must cover the full duration of the SMP monitoring period and provide a comprehensive benefit-risk assessment based on all available Thai and global post-market data at the time of submission. The quality of this submission directly determines whether Thai FDA lifts the SMP condition or extends monitoring. A PSUR that is incomplete, poorly structured, or that presents safety data without meaningful analysis will not support a successful SMP conversion.
A pharmacovigilance system in Thailand is not a reporting inbox. It is a set of processes, responsibilities, and documentation standards that must be in place before the product is approved and must function reliably from the first day of commercial distribution.
The LAR must designate a responsible person for pharmacovigilance. This individual is accountable for ensuring that adverse event reports are received, assessed, and submitted to Thai FDA within the required timelines. The pharmacovigilance responsible person must have sufficient seniority and authority to make decisions about report submission without delay.
Written SOPs must cover the full pharmacovigilance process: receipt of adverse event reports from all sources, medical assessment of seriousness and expectedness, causality assessment, report preparation, and submission to Thai FDA. These SOPs must be current, staff must be trained on them, and training records must be maintained. Thai FDA may inspect pharmacovigilance systems as part of a GMP inspection or a standalone pharmacovigilance audit.
The LAR's Thailand pharmacovigilance process must connect to the foreign manufacturer's global safety database. Reports from Thailand must feed into the global database; reports from other markets involving the same product must be assessed for their relevance to the Thai population and forwarded to the LAR if they meet the criteria for expedited reporting in Thailand. An LAR that operates its Thailand pharmacovigilance entirely separately from the manufacturer's global system will miss reports and violate its reporting obligations.
As LAR for our clients' products in Thailand, we are the pharmacovigilance reporting entity to Thai FDA. We receive adverse event reports, assess them against Thai FDA's seriousness and expectedness criteria, and submit within the mandatory timelines. We maintain the documentation that demonstrates we did so.
We do not treat the 7-day and 15-day reporting windows as targets to work toward. Reports are assessed and submitted as soon as they are complete and verified. For products under SMP conditions, we manage the periodic safety reporting schedule and prepare the end-of-SMP PSUR as a substantive regulatory document, not a form-filling exercise.
For manufacturers integrating Thailand into an existing global pharmacovigilance system, we work directly with their global safety team to establish the routing and escalation protocol for Thailand-relevant reports. We define what comes to us, how quickly, and in what format, before the first shipment arrives.